ALCLS.PA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 13:51):

Stats
Dagens volum	31 522.00
Gjennomsnittsvolum	84 070.00
Markedsverdi	171.84M
EPS	$0 ( 2024-04-03 )
Neste inntjeningsdato	( $0 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.830
ATR14	$0.0150 (0.63%)

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: 0.98 (very strong)

Signal:(50.209) Expect same movement, but be aware

Cellectis SA Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cellectis SA Korrelasjon - Valuta/Råvare

0.43
( neutral )

0.42
( neutral )

0.00
( neutral )

-0.39
( neutral )

-0.22
( neutral )

Cellectis SA Økonomi

Annual	2022
Omsetning:	$19.17M
Bruttogevinst:	$17.40M (90.76 %)
EPS:	$-2.17

FY	2022
Omsetning:	$19.17M
Bruttogevinst:	$17.40M (90.76 %)
EPS:	$-2.17

FY	2021
Omsetning:	$57.29M
Bruttogevinst:	$25.93M (45.26 %)
EPS:	$-1.910

FY	2020
Omsetning:	$73.95M
Bruttogevinst:	$37.67M (50.95 %)
EPS:	$-1.910

Financial Reports:

No articles found.

Cellectis SA

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.